DDMAC issues untitled letter concerning Ista journal ad

Share this article:
The FDA's Division of Drug Marketing, Advertising and Communications (DDMAC) issued an untitled letter to Ista Pharmaceuticals concerning a journal advertisement for Vitrase (hyaluonidase injection), indicated for the treatment of vitreous hemorrhage and diabetic retinopathy.
In the letter, DDMAC said the journal ad is false or misleading because it fails to reveal material
facts, thus minimizing the risks associated with treatment with Vitrase. "DDMAC requests that Ista immediately cease the dissemination of violative promotional materials for Vitrase," the letter stated.
A spokesperson for Ista was not immediately available for comment.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in News

Email Newsletters

More in News

Five things for Pharma Marketers to know: Friday, August 29

Five things for Pharma Marketers to know: Friday, ...

Takeda closes out a good-news, bad-news kind of week, AstraZeneca adds a new clinical trial for its experimental PD-1, and researchers link a funeral to the Ebola outbreak.

Amgen sends PCSK9 to FDA

Amgen sends PCSK9 to FDA

Evolocumab holds the FDA's first filed biologics license application for the class.

Consultants expect M&A tempo to continue

Consultants expect M&A tempo to continue

PwC anticipates that divestitures will fuel late-2014 deals, but notes that the noise around early deals and the financials don't fully match up.